| Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance N Aghel, DH Delgado, JH Lipton Vascular Health and Risk Management, 293-303, 2017 | 85 | 2017 |
| Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran—a multicenter study SM Hosseini‐Moghaddam, H Keyvani, H Kasiri, SM Kazemeyni, A Basiri, ... Journal of medical virology 78 (5), 569-573, 2006 | 74 | 2006 |
| Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis MM Alhussein, A Mokbel, T Cosman, N Aghel, EH Yang, SD Mukherjee, ... CJC open 3 (11), 1372-1382, 2021 | 35 | 2021 |
| The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer F Cirne, N Aghel, JA Petropoulos, L Klotz, DJ Lenihan, F Saad, J Pinthus, ... European Heart Journal-Cardiovascular Pharmacotherapy 8 (3), 253-262, 2022 | 31 | 2022 |
| Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up N Aghel, JH Lipton, EG Atenafu, DDH Kim, DH Delgado Clinical Lymphoma Myeloma and Leukemia 17 (12), 870-878. e1, 2017 | 30 | 2017 |
| Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study G Fervaha, JP Izard, DA Tripp, N Aghel, B Shayegan, L Klotz, T Niazi, ... Canadian Urological Association Journal 15 (6), 181, 2021 | 19 | 2021 |
| Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease D Leong, N Aghel, C Hillis, D Siegal, S Karampatos, S Rangarajan, ... Heart 107 (8), 667-673, 2021 | 17 | 2021 |
| Mechanisms of cardiovascular toxicity of BCR-ABL1 tyrosine kinase inhibitors in chronic myelogenous leukemia D Gustafson, JE Fish, JH Lipton, N Aghel Current Hematologic Malignancy Reports 15, 20-30, 2020 | 14 | 2020 |
| The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis H Klimis, JH Pinthus, N Aghel, E Duceppe, V Fradet, I Brown, ... Cardio Oncology 5 (1), 70-81, 2023 | 13 | 2023 |
| Cardiac outcomes in pregnant women with treated cancer S Liu, N Aghel, L Belford, CK Silversides, M Nolan, E Amir, C Maxwell, ... Journal of the American College of Cardiology 72 (17), 2087-2089, 2018 | 11 | 2018 |
| Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry J Nowatzke, P Guedeney, N Palaskas, L Lehmann, S Ederhy, H Zhu, ... European Journal of Cancer 177, 197-205, 2022 | 10 | 2022 |
| Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines? N Aghel, DH Delgado, JH Lipton Leukemia 32 (10), 2095-2104, 2018 | 9 | 2018 |
| Recurrent myocarditis induced by immune-checkpoint inhibitor treatment is accompanied by persistent inflammatory markers despite immunosuppressive treatment N Aghel, D Gustafson, A Di Meo, M Music, I Prassas, MA Seidman, ... JCO precision oncology 5, 2021 | 7 | 2021 |
| Diagnostic performance of abnormal nulling on cardiac magnetic resonance imaging look locker inversion time sequence in differentiating cardiac amyloidosis types A Tavoosi, B Yu, N Aghel, GR Karur, M Pakkal, R Wald, BJ Wintersperger, ... Journal of Thoracic Imaging 35 (5), 334-339, 2020 | 6 | 2020 |
| Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab S Zhou, F Cirne, J Chow, A Zereshkian, L Bordeleau, S Dhesy-Thind, ... The Oncologist 28 (9), e712-e722, 2023 | 4 | 2023 |
| Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review DP Leong, F Cirne, N Aghel, RC Baro Vila, GD Cavalli, PM Ellis, ... Cardio Oncology 5 (4), 415-430, 2023 | 3 | 2023 |
| Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors N Aghel, RC Baro Vila, M Lui, C Hillis, DP Leong Current Cardiology Reports 25 (9), 941-958, 2023 | 2 | 2023 |
| Invasive cardiac interventions in patients with active, advanced solid and hematologic malignancies: a conceptual framework: JACC: CardioOncology state-of-the-art review DP Leong, F Cirne, N Aghel, RCB Vila, GD Cavalli, PM Ellis, JS Healey, ... JACC: CardioOncology, 2023 | 1 | 2023 |
| Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis (vol 29, pg 3100, 2023) C Fenioux, B Abbar, S Boussouar, M Bretagne, JR Power, JJ Moslehi, ... NATURE MEDICINE, 2024 | | 2024 |
| High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors N Aghel, D Gustafson, D Delgado, EG Atenafu, JE Fish, JH Lipton Leukemia & Lymphoma 64 (12), 2008-2017, 2023 | | 2023 |
